Clinical trial NCT06558422: Human Models of Selective Insulin Resistance: Pancreatic Clamp
Official title: Human Models of Selective Insulin Resistance: Pancreatic Clamp
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Insulin Resistance
Hyperinsulinemia
Metabolic Dysfunction Associated Steatotic Liver Disease
Non-Alcoholic Fatty Liver Disease
Prediabetic State
Obesity
Keywords: Insulin resistance
Hyperinsulinemia
Diabetes
Non-alcoholic fatty liver disease
Metabolic dysfunction associated steatotic liver disease
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: University of California, Berkeley
name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2024-08-16
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: All participants will undergo (i.e., cross over between) both pancreatic clamp protocols (MH, RE) separated by 2-8 weeks. The order of the clamp protocols (i.e., MH \> RE, RE \> MH) will be randomized.
Primary purpose: BASIC_SCIENCE

Brief summary: This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the impact of lowering insulin levels on hepatic glucose production (HGP) vs de novo lipogenesis (DNL) in people with insulin resistance. The investigators will recruit participants with a history of overweight/obesity and evidence of insulin resistance (i.e., fasting hyperinsulinemia plus prediabetes and/or impaired fasting glucose and/or Homeostasis Model Assessment of Insulin Resistance \[HOMA-IR\] score \>=2.73), and with evidence of metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo two pancreatic clamp procedures -- one in which serum insulin levels are maintained near hyperinsulinemic baseline (Maintenance Hyperinsulinemia or "MH" Protocol) and the other in which serum insulin levels are lowered by 50% (Reduction toward Euinsulinemia or "RE" Protocol). In both clamps the investigators will use stable-isotope tracers to monitor hepatic glucose and triglyceride metabolism. The primary outcome will be the impact of steady-state clamp insulinemia on HGP vs DNL.

Detailed description: Although high blood sugar and risk of heart disease are the most well-known health effects of type 2 diabetes (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), in which too much fat accumulates in the liver, has come to be recognized as another important complication. Unchecked, MASLD can progress to severe liver inflammation, liver failure, and even liver cancer. The investigators suspect that high levels of the blood sugar-lowering hormone insulin leads to excessive fat production by the liver, and so lowering insulin levels might help to improve MASLD. In order to answer this question, the investigators will recruit people with MASLD at risk for T2DM to perform a "pancreatic clamp" - a procedure in which the body's production of insulin is temporarily shut off and then replaced at the same or lower levels. Again, the investigators expect that lowering insulin levels will lower fat production ("de novo lipogenesis" or DNL). Research participants in this prospective, randomized, controlled (crossover) study will therefore undergo two pancreatic clamps in random order: one roughly maintaining their own internal ("basal") insulin level ("MH Protocol") and one in which the investigators lower that basal insulin level by 50% ("RE Protocol"). In each case, the investigators will observe the absolute and relative changes in the liver's production of glucose (hepatic glucose production, HGP) and of triglycerides (de novo lipogenesis, DNL) using stable-isotope tracers.

Eligibility criteria: Inclusion Criteria:

* Men and women, ages 18-65 years
* Body mass index of 27-50 kg/m2
* Able to understand written and spoken English and/or Spanish
* Evidence of insulin resistance, represented by any or all of the following criteria:

  * Meeting either of the American Diabetes Association's definitions for prediabetes or Impaired fasting glucose (IFG) within the previous year and on screening labs:

    1. Prediabetes: Hemoglobin A1c 5.7-6.4%
    2. IFG: plasma glucose of 100-125 mg/dL after 8-h fast
* Homeostasis Model of Insulin Resistance (HOMA-IR) score ≥ 2.73
* Fasting hyperinsulinemia (fasting insulin level ≥ 13 µU/mL) on screening labs
* Presence of uncomplicated MASLD, defined by vibration-controlled transient elastography (VCTE) as a steatosis score S1-S3 + fibrosis score F0-F2
* Written informed consent (in English or Spanish) and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations.

Exclusion Criteria:

* Unable to provide informed consent in English or Spanish
* Unwillingness to use only bedpan or urinal to void or to refrain from non-emergent mobile device use during the clamp
* Documented weight loss of ≥ 5% of baseline within the previous 3 months
* Abnormal blood pressure (including on treatment, if prescribed)

  * Systolic blood pressure \< 90 mm Hg or \> 160 mm Hg, and/or
  * Diastolic blood pressure \< 60 mm Hg or \> 100 mm Hg
* Abnormal resting heart rate: \< 60 or ≥ 110 bpm

  * Sinus brady- or tachycardia that has been worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion
* Abnormal screening electrocardiogram (or if on file, performed within previous 90 days)
* Laboratory evidence of diabetes mellitus:

  * Hemoglobin A1c ≥ 6.5%, and/or
  * Fasting plasma glucose ≥ 126 mg/dL
* Positive qualitative β-hCG (Human chorionic gonadotropin, β subunit) (i.e., pregnancy test) in women of childbearing potential
* Positive urine drug screen, except for lawfully prescribed medications and/or marijuana
* Liver function abnormalities (either of the following)

  * Transaminases (AST or ALT) \> 3.0 x the upper limit of normal
  * Total bilirubin \> 1.25 x the upper limit of normal
* Fasting serum triglycerides at screening ≥ 400 mg/dL
* Abnormal screening serum electrolytes that are considered potentially significant according to the clinical judgment of the PI
* Abnormal complete blood count (CBC) (any of the following)

  * Hemoglobin \< 10 g/dL or hematocrit \< 30%
  * Platelet count \< 100,000/µL
* Women currently pregnant, measured by serum and/or urine β-hCG, or trying to become pregnant
* Women currently breastfeeding
* History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes):

  * Hemoglobin A1c ≥ 6.5%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency
  * Plasma glucose ≥ 126 mg/dL after 8-h fast
  * Plasma glucose of ≥ 200 mg/dL at 2 h after ingestion of a 75-g glucose load
  * Random plasma glucose ≥ 200 mg/dL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state
* History of gestational diabetes mellitus within the previous 5 years
* Use of most antidiabetic medications within the 30 days prior to screening

  * Excluded: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin
  * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening
* Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)
* Known diagnoses of familial combined hyperlipidemia or familial chylomicronemia syndrome
* Use of certain lipid-lowering drugs within 30 d prior to screening visit:

  * Fibrates (e.g., fenofibrate, clofibrate, gemfibrozil)
  * Prescription-strength omega-3 fatty acids (e.g., Lovaza®, Vascepa®)
* Known, documented history, at the time of screening, of any of the following medical conditions:

  * Pancreatic pathology
  * Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)
  * Chronic kidney disease, Stage 3 or higher (estimated glomerular filtration rate \< 60 mL min-1 1.73 m-2), of any cause
  * Advanced or severe liver disease (including fibrosis scores of F3-F4 on screening VCTE)
  * Gallstone disease
  * Chronic viral illness
  * Malabsorptive conditions (active)
  * Active seizure disorder (including controlled with antiepileptic drugs)
  * Psychiatric diseases causing functional impairment and/or requiring use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine), monoamine oxidase inhibitors, tricyclic antidepressants, or lithium
  * Known adrenal disease
  * Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation
  * Bleeding disorders, including due to anticoagulation, or significant anemia (see above)
  * Active malignancy, or hormonally active benign neoplasm
* Clinical concern for increased risk of volume overload, including due to medications and/or heart/liver/kidney problems, as listed above
* Clinical concern for increased risk of hypokalemia, including low potassium on screening labs (i.e., below lower limit of normal), use of certain medications, or any medical conditions listed above
* Use of certain medications currently or within 30 d prior to screening:

  * Prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for:
  * Use of drugs prescribed for indications other than the exclusionary diagnoses/purposes listed above, e.g., antiepileptic drugs used for non-seizure indications, ACEi (angiotensin-converting enzyme inhibitor) / ARB (angiotensin receptor blocker) used for uncomplicated hypertension rather than for congestive heart failure, etc. Note, as above, that antidiabetic drugs except metformin within 30 days of screening are excluded.
  * Loop diuretics (furosemide, torsemide, ethacrynic acid)
  * Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted
  * Fludrocortisone
  * Beta blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem)
* History of certain weight-loss (bariatric) surgery, including:

  * Roux-en-Y gastric bypass
  * Biliopancreatic diversion
  * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months
* Clinical concern for alcohol overuse, including recent documented history during screening and/or participant report of regularly consuming more than 2 drinks per day for males or 1 drink per day for females.
* Positive urine drug screen, with exceptions for:

  * Lawfully prescribed medications
  * Marijuana/THC positivity, provided that the participant agrees not to use it during the same period that they will abstain from alcohol
* History of severe infection or ongoing febrile illness within 14 days of screening
* Any other disease, condition, or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and/or interfere with the analysis of study data.
* Known allergy/hypersensitivity to any component of the medicinal product formulations, foods (including soy, dairy, peanuts, tree nuts, or egg), IV infusion equipment, plastics, adhesive or silicone, history of infusion site reactions with IV administration of other medicines, or ongoing clinically important allergy/hypersensitivity as judged by the investigator.
* Concurrent enrollment in another clinical study of any investigational drug therapy within 30 days prior to screening or within 5 half-lives of an investigational agent, whichever is longer.

Primary outcomes:
measure: Hepatic de novo lipogenesis (DNL) (absolute value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Hepatic de novo lipogenesis (DNL) (relative value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Endogenous glucose production (EGP) (absolute value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Endogenous glucose production (EGP) (relative value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Plasma glucose level
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Serum insulin level
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
Secondary outcomes:
measure: Serum or plasma triglyceride level
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Plasma free fatty acids level
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Glucose kinetics: rate of appearance (absolute value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Glucose kinetics: rate of appearance (relative value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Glucose kinetics: rate of disappearance (absolute value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Glucose kinetics: rate of disappearance (relative value)
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
Other outcomes:
measure: Serum C-peptide level
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Plasma glucagon level
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
measure: Serum growth hormone level
timeFrame: Up to 6.5 hours of pancreatic clamp protocol
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Joshua R Cook, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: